• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ambiq Reports Third Quarter 2025 Financial Results

    11/6/25 4:15:00 PM ET
    $AMBQ
    Semiconductors
    Technology
    Get the next $AMBQ alert in real time by email

    Expects strong fourth quarter net sales of $18.5 – $19.5 million, marking the highest quarterly revenue of 2025

    Third quarter net sales of $18.2 million exceeded guidance, driven by ongoing customer strength and product adoption

    Third quarter GAAP gross margin of 42.3%; Non-GAAP gross margin of 44.8%, reflecting strategic pivot to higher-value, Edge AI customers and markets

    Ambiq Micro, Inc. ("Ambiq") (NYSE:AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced financial results for the third quarter of 2025.

    Third Quarter and Recent Highlights

    • AI-driven margin expansion: Delivered double-digit gross profit growth on lower year-over-year sales, reflecting strategic repositioning to focus on higher-value edge AI markets and customers.
    • Net loss improvement: GAAP net loss attributable to common stockholders improved by $0.7 million year-over-year to $9.0 million or $0.72 per share; non-GAAP net loss attributable to common stockholders improved $1.8 million year-over-year to $4.0 million or $0.22 per share on a pro forma basis.
    • Broadened edge AI SoC portfolio: Launched Apollo510 Lite, expanding reach across personal devices, medical/ healthcare, industrial edge and smart home and building markets.
    • Accelerated AI enablement: Enhanced neuralSPOT SDK and Helia runtimes to streamline model deployment and speed customer time-to-market.
    • Recognized innovation leadership: SPOT platform honored as one of TIME's Best Inventions of 2025.

    Management Commentary

    "Our third quarter results underscore the strength of our business and the growing demand for energy-efficient AI solutions at the edge. Our growth is accelerating with increased orders from existing customers, multiple design wins from new customers and growing Apollo5 production ramps," said Fumihide Esaka, CEO of Ambiq. "Our fourth quarter guidance is well ahead of consensus expectations and would mark the strongest quarterly performance of the year. Looking ahead, we believe that 2025 represents the beginning of a much larger opportunity for Ambiq. Our energy-efficient solutions are enabling the next wave of edge AI innovation while positioning us for meaningful, sustainable growth."

    Summary of Reported Third Quarter 2025 Results

    GAAP

    ($ in thousands except for margin)

     

    Three months

    ended

    September 30,

     

    Three months

    ended

    June 30,

     

    Three months

    ended

    September 30,

     

    Quarter

    over quarter

    change

     

    Year over

    year change

     

     

    2025

     

    2025

     

    2024

     

     

     

     

    Net sales

     

    $

    18,165

     

     

    $

    17,873

     

     

    $

    20,266

     

     

     

    1.6

    %

     

     

    -10.4

    %

    Gross profit

     

    $

    7,677

     

     

    $

    7,170

     

     

    $

    6,598

     

     

     

    7.1

    %

     

     

    16.4

    %

    Gross margin

     

     

    42.3

    %

     

     

    40.1

    %

     

     

    32.6

    %

     

    2.2 pts

     

     

    9.7 pts

     

    Operating expense

     

    $

    17,720

     

     

    $

    15,967

     

     

    $

    16,687

     

     

     

    11.0

    %

     

     

    6.2

    %

    Net loss attributable to common stockholders

     

    $

    (9,002

    )

     

    $

    (8,496

    )

     

    $

    (9,743

    )

     

    $

    (506

    )

     

    $

    741

     

    NON-GAAP FINANCIAL MEASURES

    ($ in thousands except for margin)

     

    Three months

    ended

    September 30,

     

    Three months

    ended

    June 30,

     

    Three months

    ended

    September 30,

     

    Quarter

    over quarter

    change

     

    Year over

    year change

     

     

    2025

     

    2025

     

    2024

     

     

     

     

    Non-GAAP Gross profit

     

    $

    8,141

     

     

    $

    7,640

     

     

    $

    6,968

     

     

     

    6.6

    %

     

     

    16.8

    %

    Non-GAAP Gross margin

     

     

    44.8

    %

     

     

    42.7

    %

     

     

    34.4

    %

     

    2.1 pts

     

     

    10.4 pts

     

    Non-GAAP Operating expense

     

    $

    13,162

     

     

    $

    13,819

     

     

    $

    13,019

     

     

     

    -4.8

    %

     

     

    1.1

    %

    Non-GAAP Net loss attributable to common stockholders

     

    $

    (3,977

    )

     

    $

    (5,862

    )

     

    $

    (5,743

    )

     

    $

    1,885

     

     

    $

    1,766

     

    Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expense and non-GAAP net loss attributable to common stockholders are non-GAAP financial measures. See "Non-GAAP Financial Measures" below for definitions of each of these measures, and the tables accompanying this press release for reconciliations of these measures to their most comparable GAAP measure.

    Fourth Quarter Business Outlook

    Ambiq's current expectations for the fourth quarter of 2025 ending December 31, 2025, include the following:

    • Net sales within a range of $18.5 million to $19.5 million
    • Non-GAAP loss per share within a range of ($0.44) to ($0.34) based on 18.2 million pro forma shares, which represents the company's post-IPO common shares outstanding1

    1Ambiq's financial outlook is based on assumptions that it believes to be reasonable as of the date of this release, but may be materially affected by many factors, as discussed below in "Forward-Looking Statements." Actual results may vary from the guidance and the variations may be material. We undertake no intent or obligation to publicly update or revise this outlook, whether as a result of new information, future events or otherwise, except as required by law. The Company is unable to include a reconciliation of forward-looking non-GAAP net loss per share per share to net loss per share, the most directly comparable GAAP measure, without unreasonable effort due to the high variability with respect to the impact of items such as income taxes, depreciation and amortization, stock-based compensation expense, gain on nonmonetary transaction, severance costs, initial public offering (IPO) and other transaction costs, warrant valuation and other items that are excluded from this non-GAAP measure.

    Conference Call

    Ambiq will host a conference call for analysts and investors today at 5:00 p.m. Eastern Time. Interested participants can access the call by dialing 1-800-715-9871 and providing conference ID 3633496. International callers may join the call by dialing +1-646-307-1963, using the same code. The call will also be available as a live and archived webcast on the Events & Presentations section of Ambiq's Investor Relations website.

    A telephone replay of the conference call will be available approximately two hours after the call through Thursday, 13th November 2025, at 11:59 PM EST. The replay can be accessed by dialing 1-800-770-2030 and using the playback ID 3633496. International callers should dial +1-647-362-9199 and enter the same ID at the prompt.

    About Ambiq Micro

    Headquartered in Austin, Texas, Ambiq's mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. Ambiq enables its customers to deliver AI compute at the edge where power consumption challenges are the most severe. Ambiq's technology innovations, built on the patented and proprietary subthreshold power optimized technology (SPOT®), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. Ambiq has powered over 280 million devices to date. For more information, visit www.ambiq.com.

    Non-GAAP Financial Measures

    Ambiq supplements its reporting of financial information determined under generally accepted accounting principles in the United States of America (GAAP), including the use of non-GAAP net loss attributable to common stockholders, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP R&D expenses, non-GAAP SG&A expenses, non-GAAP net loss attributable to common stockholders and pro forma non-GAAP loss per share attributable to common stockholders. These non-GAAP financial measures help make strategic decisions, establish budgets and operational goals for managing the business, analyzing financial results, and evaluating business performance. Ambiq defines non-GAAP gross profit as gross profit adjusted to exclude expenses not directly attributable to gross profit, such as depreciation and amortization, gain on nonmonetary transaction, and stock-based compensation. Ambiq defines non-GAAP gross margin as non-GAAP gross profit as a percentage of net sales. Ambiq defines non-GAAP operating expenses, non-GAAP R&D expenses and non-GAAP SG&A expenses as operating expenses, R&D expenses and SG&A expenses, as applicable, adjusted to exclude expenses not directly attributable to operating expenses, R&D expenses and SG&A expenses, as applicable, such as depreciation and amortization, stock-based compensation, severance costs, IPO-related bonus and IPO and other transaction costs Ambiq defines non-GAAP net loss attributable to common stockholders as net loss attributable to common stockholders adjusted to exclude expenses not directly attributable to the performance of operations, such as income taxes, depreciation and amortization, stock-based compensation, gain on nonmonetary transaction, severance costs, IPO-related bonus, IPO and other transaction costs and warrant valuation. Ambiq defines pro forma non-GAAP loss per share attributable to common stockholders as non-GAAP net loss attributable to common stockholders divided by pro forma common shares outstanding, which gives effect to the automatic conversion of all outstanding redeemable convertible preferred stock, exercise of warrants to purchase common stock and settlement of IPO vesting RSUs into common stock that occurred immediately prior to the completion of our initial public offering, as well as the issuance of shares in our initial public offering, as if such transactions had occurred on July 1, 2025.

    Ambiq believes these non-GAAP financial measures provide additional tools for investors to use in comparing core business and results of operations over multiple periods with other companies in the industry, many of which present similar non-GAAP financial measures. However, Ambiq's presentation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP R&D expenses, non-GAAP SG&A expenses, non-GAAP net loss attributable to common stockholders and pro forma non-GAAP loss per share attributable to common stockholders may not be comparable to similarly titled measures reported by other companies due to differences in the way that these measures are calculated. These non-GAAP measures have limitations, and should not be considered as the sole measures of our performance and should not be considered in isolation from, or as a substitute for, the most comparable measure calculated in accordance with GAAP.

    Forward-Looking Statements

    The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as "believes," "expects," "may," "will," "should," "seeks," "intends," "plans," "estimates," or "anticipates," or similar expressions which concern our strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to Ambiq's expectations around its strategic initiatives, growth trajectory and expected fourth quarter business outlook. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify including those described in the section titled "Risk Factors" in Ambiq's Quarterly Report on 10-Q for the quarter ended June 30, 2025, as well as in other filings Ambiq may make with the SEC in the future. Ambiq's expectations, beliefs and projections are expressed in good faith and Ambiq believes there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. Ambiq undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

    AMBIQ MICRO, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    As of September 30, 2025 and December 31, 2024

    (Unaudited and in thousands, except share and per share amounts)

     

     

     

    September 30,

     

    December 31,

     

     

    2025

     

    2024

    Assets

     

     

     

     

    Current assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    146,490

     

     

    $

    60,981

     

    Accounts receivable, net

     

     

    7,006

     

     

     

    10,401

     

    Inventories, net

     

     

    16,126

     

     

     

    15,008

     

    Prepaid expenses and other current assets

     

     

    3,401

     

     

     

    2,566

     

    Total current assets

     

    $

    173,023

     

     

    $

    88,956

     

    Property, equipment and software, net of accumulated depreciation and amortization of $14,244 and $13,158, respectively

     

     

    4,350

     

     

     

    2,616

     

    Right-of-use assets, net

     

     

    732

     

     

     

    928

     

    Intangible assets, net of accumulated amortization of $9,502 and $5,082, respectively

     

     

    8,572

     

     

     

    11,729

     

    Other assets

     

     

    50

     

     

     

    49

     

    Total assets

     

    $

    186,727

     

     

    $

    104,278

     

    Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)

     

     

     

     

    Current liabilities:

     

     

     

     

    Accounts payable

     

    $

    3,305

     

     

    $

    2,933

     

    Accrued and other current liabilities

     

     

    9,559

     

     

     

    8,202

     

    Short-term lease liabilities

     

     

    402

     

     

     

    633

     

    Total current liabilities

     

    $

    13,266

     

     

    $

    11,768

     

    Long-term lease liabilities

     

     

    369

     

     

     

    333

     

    Warrant liabilities

     

     

    —

     

     

     

    112

     

    Other long-term liabilities

     

     

    3,305

     

     

     

    6,317

     

    Total liabilities

     

    $

    16,940

     

     

    $

    18,530

     

    Commitments and contingencies (Note 6)

     

     

     

     

    Redeemable convertible preferred stock, $0.000001 par value; 10,000,000 shares authorized; 0 and 341,496,158 shares issued and outstanding at September 30, 2025 and December 31, 2024

     

    $

    —

     

     

    $

    378,150

     

    Stockholders' equity (deficit):

     

     

     

     

    Common stock, $0.000001 par value; 500,000,000 shares authorized; 18,238,462 shares and 434,720 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively

     

     

    —

     

     

     

    —

     

    Additional paid-in-capital

     

     

    516,273

     

     

     

    28,368

     

    Accumulated deficit

     

     

    (346,032

    )

     

     

    (320,250

    )

    Accumulated other comprehensive loss

     

     

    (454

    )

     

     

    (520

    )

    Total stockholders' equity (deficit)

     

     

    169,787

     

     

     

    (292,402

    )

    Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)

     

    $

    186,727

     

     

    $

    104,278

     

    AMBIQ MICRO, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    For the three and nine months ended September 30, 2025 and 2024

    (Unaudited and in thousands)

     

     

     

    Three Months Ended

     

    Nine Months Ended

     

     

    September 30,

    2025

     

    September 30,

    2024

     

    September 30,

    2025

     

    September 30,

    2024

    Net sales

     

    $

    18,165

     

     

    $

    20,266

     

     

    $

    51,770

     

     

    $

    55,728

     

    Cost of sales

     

     

    10,488

     

     

     

    13,668

     

     

     

    28,534

     

     

     

    36,485

     

    Gross profit

     

     

    7,677

     

     

     

    6,598

     

     

     

    23,236

     

     

     

    19,243

     

    Operating expenses:

     

     

     

     

     

     

     

     

    Research and development

     

     

    8,889

     

     

     

    9,568

     

     

     

    26,474

     

     

     

    28,395

     

    Selling, general, and administrative

     

     

    8,831

     

     

     

    7,119

     

     

     

    24,343

     

     

     

    21,090

     

    Total operating expenses

     

     

    17,720

     

     

     

    16,687

     

     

     

    50,817

     

     

     

    49,485

     

    Loss from operations

     

     

    (10,043

    )

     

     

    (10,089

    )

     

     

    (27,581

    )

     

     

    (30,242

    )

    Other income, net

     

     

    1,044

     

     

     

    664

     

     

     

    1,820

     

     

     

    797

     

    Loss before income taxes

     

     

    (8,999

    )

     

     

    (9,425

    )

     

     

    (25,761

    )

     

     

    (29,445

    )

    Provision for income taxes

     

     

    3

     

     

     

    13

     

     

     

    21

     

     

     

    25

     

    Net loss

     

    $

    (9,002

    )

     

    $

    (9,438

    )

     

    $

    (25,782

    )

     

    $

    (29,470

    )

    Deemed dividends

     

     

    —

     

     

     

    (305

    )

     

     

    —

     

     

     

    (2,724

    )

    Net loss attributable to common stockholders

     

    $

    (9,002

    )

     

    $

    (9,743

    )

     

    $

    (25,782

    )

     

    $

    (32,194

    )

    Net loss per share attributable to common stockholders, basic and diluted

     

    $

    (0.72

    )

     

    $

    (26.03

    )

     

    $

    (5.73

    )

     

    $

    (87.51

    )

    Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted

     

     

    12,464,236

     

     

     

    374,270

     

     

     

    4,495,701

     

     

     

    367,888

     

    Comprehensive loss:

     

     

     

     

     

     

     

     

    Currency translation adjustment

     

     

    (14

    )

     

     

    56

     

     

     

    66

     

     

     

    107

     

    Comprehensive loss

     

    $

    (9,016

    )

     

    $

    (9,382

    )

     

    $

    (25,716

    )

     

    $

    (29,363

    )

    Deemed dividends

     

     

    —

     

     

     

    (305

    )

     

     

    —

     

     

     

    (2,724

    )

    Comprehensive loss attributable to common stockholders

     

    $

    (9,016

    )

     

    $

    (9,687

    )

     

    $

    (25,716

    )

     

    $

    (32,087

    )

    AMBIQ MICRO, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    For the nine months ended September 30, 2025 and 2024

    (Unaudited and in thousands)

     

     

     

    For the nine months ended September 30,

     

     

    2025

     

    2024

    Cash flows from operating activities

     

     

     

     

    Net loss

     

    $

    (25,782

    )

     

    $

    (29,470

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

     

    Depreciation and amortization

     

     

    5,568

     

     

     

    4,631

     

    Stock-based compensation

     

     

    3,684

     

     

     

    4,311

     

    Gain on receipt of nonmonetary tangible assets

     

     

    (1,600

    )

     

     

    (1,600

    )

    Change in right-of-use assets

     

     

    606

     

     

     

    747

     

    Non-cash issuance of warrants

     

     

    —

     

     

     

    1,940

     

    Change in warrant valuations and cancellations

     

     

    60

     

     

     

    (51

    )

    Other

     

     

    (110

    )

     

     

    —

     

    Changes in operating assets and liabilities

     

     

     

     

    Accounts receivable

     

     

    3,484

     

     

     

    (2,851

    )

    Inventories

     

     

    (1,118

    )

     

     

    3,202

     

    Prepaid expenses and other assets

     

     

    (823

    )

     

     

    (1,444

    )

    Other long-term assets

     

     

    —

     

     

     

    361

     

    Accounts payable

     

     

    (956

    )

     

     

    1,932

     

    Accrued and other current liabilities

     

     

    1,584

     

     

     

    (2,966

    )

    Other long-term liabilities

     

     

    (174

    )

     

     

    (446

    )

    Net cash used in operating activities

     

     

    (15,577

    )

     

     

    (21,704

    )

    Cash flows from investing activities

     

     

     

     

    Purchase of intangible assets

     

     

    (3,687

    )

     

     

    (2,145

    )

    Purchases of property, equipment and software

     

     

    (1,162

    )

     

     

    (243

    )

    Net cash used in investing activities

     

     

    (4,849

    )

     

     

    (2,388

    )

    Cash flows from financing activities

     

     

     

     

    Proceeds from issuance of common stock in connection with initial public offering, net of offering costs, underwriting discounts and commissions

     

     

    99,843

     

     

     

    —

     

    Proceeds from issuance of preferred stock, net of issuance costs

     

     

    —

     

     

     

    57,983

     

    Proceeds from exercise of stock options

     

     

    353

     

     

     

    349

     

    Proceeds from exercise of warrants

     

     

    5,702

     

     

     

    —

     

    Net cash provided by financing activities

     

     

    105,898

     

     

     

    58,332

     

    Effect of exchange rate changes on cash and cash equivalents

     

     

    37

     

     

     

    8

     

    Net increase in cash and cash equivalents

     

     

    85,509

     

     

     

    34,248

     

    Cash and cash equivalents at beginning of period

     

     

    60,981

     

     

     

    27,321

     

    Cash and cash equivalents at end of period

     

    $

    146,490

     

     

    $

    61,569

     

    Supplemental disclosure of non-cash investing and financing activities

     

     

     

     

    Intangible assets in accounts payable, accrued and other long-term liabilities

     

     

    7,904

     

     

     

    3,456

     

    Gain on receipt of nonmonetary tangible asset

     

     

    1,600

     

     

     

    1,600

     

    Right-of-use assets obtained in exchange for new operating lease liabilities

     

     

    383

     

     

     

    1,124

     

    Deemed dividends

     

    —

     

     

     

    2,724

     

    The following table reconcile the most directly comparable GAAP financial measure to each of these non-GAAP financial measures.

    Non-GAAP Net Loss:

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

    Three

    months

    ended June 30,

     

     

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

     

    (in thousands)

    Net loss attributable to common stockholders

     

    $

    (9,002

    )

     

    $

    (9,743

    )

     

    $

    (25,782

    )

     

    $

    (32,194

    )

     

    $

    (8,496

    )

    Add:

     

     

     

     

     

     

     

     

     

     

    Income taxes

     

     

    3

     

     

     

    13

     

     

     

    21

     

     

     

    25

     

     

     

    14

     

    Depreciation and amortization

     

     

    1,754

     

     

     

    1,462

     

     

     

    5,568

     

     

     

    4,631

     

     

     

    1,853

     

    Stock-based compensation

     

     

    2,068

     

     

     

    2,122

     

     

     

    3,684

     

     

     

    4,311

     

     

     

    765

     

    Gain on nonmonetary transaction

     

     

    —

     

     

     

    —

     

     

     

    (1,600

    )

     

     

    (1,600

    )

     

     

    —

     

    Severance costs

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    706

     

     

     

    —

     

    IPO-related bonus

     

     

    1,200

     

     

     

    —

     

     

     

    1,200

     

     

     

    —

     

     

     

    —

     

    IPO and other transaction costs

     

     

    —

     

     

     

    454

     

     

     

    1,793

     

     

     

    454

     

     

     

    —

     

    Warrant valuation

     

     

    —

     

     

     

    (51

    )

     

     

    60

     

     

     

    (51

    )

     

     

    2

     

    Non-GAAP net loss attributable to common stockholders

     

    $

    (3,977

    )

     

    $

    (5,743

    )

     

    $

    (15,056

    )

     

    $

    (23,718

    )

     

    $

    (5,862

    )

    Non-GAAP Gross Profit:

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

    Three

    months

    ended June 30,

     

     

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

     

    (in thousands)

    Gross profit

     

    $

    7,677

     

     

    $

    6,598

     

     

    $

    23,236

     

     

    $

    19,243

     

     

    $

    7,170

    Add:

     

     

     

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    439

     

     

     

    192

     

     

     

    1,431

     

     

     

    723

     

     

     

    430

     

    Stock-based compensation

     

     

    25

     

     

     

    178

     

     

     

    125

     

     

     

    280

     

     

     

    40

     

    Gain on nonmonetary transaction

     

     

    —

     

     

     

    —

     

     

     

    (1,600

    )

     

     

    (1,600

    )

     

     

    —

     

    Non-GAAP gross profit

     

    $

    8,141

     

     

    $

    6,968

     

     

    $

    23,192

     

     

    $

    18,646

     

     

    $

    7,640

     

    Non-GAAP Operating Expenses:

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

    Three

    months

    ended June 30,

     

     

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

     

    (in thousands)

     

    Operating expenses

     

    $

    17,720

     

     

    $

    16,687

     

     

    $

    50,817

     

     

    $

    49,485

     

     

    $

    15,967

     

    Less:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    1,315

     

     

     

    1,270

     

     

     

    4,137

     

     

     

    3,908

     

     

     

    1,423

     

    Stock-based compensation

     

     

    2,043

     

     

     

    1,944

     

     

     

    3,559

     

     

     

    4,032

     

     

     

    725

     

    Severance

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    706

     

     

     

    —

     

    IPO-related bonus

     

     

    1,200

     

     

     

    —

     

     

     

    1,200

     

     

     

    —

     

     

     

    —

     

    IPO and other transaction costs

     

     

    —

     

     

     

    454

     

     

     

    1,793

     

     

     

    454

     

     

     

    —

     

    Non-GAAP operating expenses

     

    $

    13,162

     

     

    $

    13,019

     

     

    $

    40,128

     

     

    $

    40,386

     

     

    $

    13,819

     

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

    Three

    months

    ended June 30,

    Research and development

     

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

     

    (in thousands)

     

     

     

     

    Operating expenses

     

    $

    8,889

     

     

    $

    9,568

     

     

    $

    26,474

     

     

    $

    28,395

     

     

    $

    8,898

     

    Less:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    1,279

     

     

     

    1,237

     

     

     

    3,925

     

     

     

    3,707

     

     

     

    1,390

     

    Stock-based compensation

     

     

    263

     

     

     

    873

     

     

     

    980

     

     

     

    2,021

     

     

     

    329

     

    Severance

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    439

     

     

     

    —

     

    IPO-related bonus

     

     

    433

     

     

     

    —

     

     

     

    433

     

     

     

    —

     

     

     

    —

     

    Non-GAAP operating expenses

     

    $

    6,915

     

     

    $

    7,458

     

     

    $

    21,136

     

     

    $

    22,228

     

     

    $

    7,179

     

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

    Three

    months

    ended June 30,

    Selling, general, and administrative

     

    2025

     

    2024

     

    2025

     

    2024

     

    2025

     

     

    (in thousands)

     

     

     

     

    Operating expenses

     

    $

    8,831

     

     

    $

    7,119

     

     

    $

    24,343

     

     

    $

    21,090

     

     

    $

    7,069

     

    Less:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Depreciation and amortization

     

     

    36

     

     

     

    33

     

     

     

    212

     

     

     

    201

     

     

     

    33

     

    Stock-based compensation

     

     

    1,781

     

     

     

    1,071

     

     

     

    2,579

     

     

     

    2,011

     

     

     

    398

     

    Severance

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    267

     

     

     

    —

     

    IPO-related bonus

     

     

    767

     

     

     

    —

     

     

     

    767

     

     

     

    —

     

     

     

    —

     

    IPO and other transaction costs

     

     

    —

     

     

     

    454

     

     

     

    1,793

     

     

     

    454

     

     

     

    —

     

    Non-GAAP operating expenses

     

    $

    6,247

     

     

    $

    5,562

     

     

    $

    18,992

     

     

    $

    18,157

     

     

    $

    6,638

     

    Non-GAAP Net Loss Per Share:

     

     

    Three months ended September 30,

     

    Nine months ended September 30,

     

     

    2025

     

    2024

     

    2025

     

    2024

    GAAP net loss attributable to common stockholder

     

    $

    (9,002

    )

     

    $

    (9,743

    )

     

    $

    (25,782

    )

     

    $

    (32,194

    )

    Weighted-average shares used in computing GAAP net loss per share

     

     

    12,464,236

     

     

     

    374,270

     

     

     

    4,495,701

     

     

     

    367,888

     

    GAAP net loss per share attributable to common stockholder

     

    $

    (0.72

    )

     

    $

    (26.03

    )

     

    $

    (5.73

    )

     

    $

    (87.51

    )

     

     

     

     

     

     

     

     

     

    Non-GAAP net loss

     

    $

    (3,977

    )

     

     

    Pro forma shares used in computing non-GAAP net loss per share(1)

     

     

    18,238,462

     

     

     

    Pro forma non-GAAP net loss per share

     

    $

    (0.22

    )

     

     

     

    (1) Pro forma common shares gives effect to the automatic conversion outstanding equity instruments and the issuance of shares in connection with the initial public offering, as if all such events had occurred as of the beginning of the period presented.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251106267263/en/

    Company Contact:

    Charlene Wan

    VP of Corporate Marketing and Investor Relations

    P: +1-512-879-2850

    E: [email protected]

    Investor Relations Contact:

    Teneo

    Christina Coronios

    E: [email protected]

    Get the next $AMBQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMBQ

    DatePrice TargetRatingAnalyst
    8/25/2025$40.00Neutral
    UBS
    8/25/2025$45.00Buy
    Stifel
    8/25/2025$48.00Buy
    Needham
    8/25/2025$42.00Neutral
    BofA Securities
    More analyst ratings

    $AMBQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Esaka Fumihide exercised 53,660 shares at a strike of $5.88, increasing direct ownership by 30% to 230,573 units (SEC Form 4)

    4 - Ambiq Micro, Inc. (0001500412) (Issuer)

    2/10/26 8:08:49 PM ET
    $AMBQ
    Semiconductors
    Technology

    Director Tautges Joseph A sold $241,800 worth of shares (7,800 units at $31.00), decreasing direct ownership by 14% to 48,746 units (SEC Form 4)

    4 - Ambiq Micro, Inc. (0001500412) (Issuer)

    1/28/26 6:15:48 PM ET
    $AMBQ
    Semiconductors
    Technology

    Chief Technology Officer Hanson Scott Mclean sold $310,000 worth of shares (10,000 units at $31.00), decreasing direct ownership by 8% to 122,818 units (SEC Form 4)

    4 - Ambiq Micro, Inc. (0001500412) (Issuer)

    1/28/26 6:12:33 PM ET
    $AMBQ
    Semiconductors
    Technology

    $AMBQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Ambiq Micro with a new price target

    UBS initiated coverage of Ambiq Micro with a rating of Neutral and set a new price target of $40.00

    8/25/25 8:11:48 AM ET
    $AMBQ
    Semiconductors
    Technology

    Stifel initiated coverage on Ambiq Micro with a new price target

    Stifel initiated coverage of Ambiq Micro with a rating of Buy and set a new price target of $45.00

    8/25/25 8:11:28 AM ET
    $AMBQ
    Semiconductors
    Technology

    Needham initiated coverage on Ambiq Micro with a new price target

    Needham initiated coverage of Ambiq Micro with a rating of Buy and set a new price target of $48.00

    8/25/25 8:11:28 AM ET
    $AMBQ
    Semiconductors
    Technology

    $AMBQ
    SEC Filings

    View All

    SEC Form 424B4 filed by Ambiq Micro Inc.

    424B4 - Ambiq Micro, Inc. (0001500412) (Filer)

    1/23/26 9:46:27 PM ET
    $AMBQ
    Semiconductors
    Technology

    SEC Form EFFECT filed by Ambiq Micro Inc.

    EFFECT - Ambiq Micro, Inc. (0001500412) (Filer)

    1/23/26 12:15:34 AM ET
    $AMBQ
    Semiconductors
    Technology

    SEC Form S-1MEF filed by Ambiq Micro Inc.

    S-1MEF - Ambiq Micro, Inc. (0001500412) (Filer)

    1/23/26 6:02:29 AM ET
    $AMBQ
    Semiconductors
    Technology

    $AMBQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ambiq Announces Pricing of Upsized Public Offering

    Ambiq Micro, Inc. ("Ambiq") (NYSE:AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the pricing of its upsized underwritten public offering of 2,679,600 shares of its common stock at a public offering price of $31.00 per share. 2,636,651 shares of common stock are being offered by Ambiq, and 42,949 shares of common stock are being offered by certain of Ambiq's stockholders. The gross proceeds to Ambiq from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ambiq, are expected to be $81.7 million. In addition, Ambiq has granted the underwriters a 30-day option to purchase up to an addit

    1/22/26 9:14:00 PM ET
    $AMBQ
    Semiconductors
    Technology

    Ambiq Announces Public Offering of Common Stock

    AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ambiq Micro, Inc. ("Ambiq") (NYSE:AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the commencement of an underwritten public offering of 2,200,000 shares of its common stock, which includes 2,157,051 shares of common stock offered by Ambiq and 42,949 shares of common stock offered by certain of Ambiq's stockholders. In addition, Ambiq expects to grant the underwriters an option for a period of 30 days to purchase up to an additional 330,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other condition

    1/21/26 7:55:10 AM ET
    $AMBQ
    Semiconductors
    Technology

    Ambiq Unveils Atomiq®, the World's First Ultra-Low Power NPU SoC Built on SPOT®

    AUSTIN, Texas, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ambiq Micro, Inc. ("Ambiq") (NYSE:AMBQ), a recognized leader in ultra-low-power semiconductor solutions for edge AI, today announced Atomiq, the highly anticipated system-on-chip (SoC) integrating a Neural Processing Unit (NPU) designed to enable real-time, always-on artificial intelligence at the edge. Built on Ambiq's Subthreshold Power Optimized Technology (SPOT) platform, Atomiq aims to establish a new benchmark for energy efficiency in demanding edge AI applications. High Performance Meets Power Efficiency As AI models continue to grow in complexity, manufacturers face a critical challenge: scaling device intelligence without compro

    1/6/26 8:30:00 AM ET
    $AMBQ
    Semiconductors
    Technology

    $AMBQ
    Financials

    Live finance-specific insights

    View All

    Ambiq Micro to Report Third Quarter 2025 Financial Results

    Ambiq Micro, Inc. (NYSE:AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025 after market close. The Company will host a conference call at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) to discuss the results. Analysts and investors are invited to join the live conference call using the following information: Date: Thursday, November 6, 2025 Time: 4:00 p.m. Central Time (5:00 p.m. Eastern Time) Conference Call Number: 1-800-715-9871 International Call Number: +1-646-307-1963 Pass code: 3633496 Additionally, a live public webcast of the earnings confe

    10/16/25 9:00:00 AM ET
    $AMBQ
    Semiconductors
    Technology

    Ambiq Micro to Announce Second Quarter 2025 Financial Results on September 4, 2025

    Ambiq Micro, Inc. (NYSE:AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, will release its second quarter 2025 financial results on Thursday, September 4, 2025 after market close. Fumihide Esaka, Chief Executive Officer, and Jeff Winzeler, Chief Financial Officer, will host a conference call at 3:30 p.m. Central Time (4:30 p.m. Eastern Time) to discuss its results. Analysts and investors are invited to join the live conference call using the following information: Date: Thursday, September 4, 2025 Time: 3:30 p.m. Central Time (4:30 p.m. Eastern Time) Conference Call Number: 1-800-715-9871 International Call Number: +1-646-307-1963 Pass code: 3633496 Ad

    8/14/25 9:00:00 AM ET
    $AMBQ
    Semiconductors
    Technology